The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.2655_2656del (p.Val886fs)

CA913191011

597005 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 73dc276a-44f8-4f4e-ad99-3769378ea110

HGVS expressions

NM_000152.5:c.2655_2656del
NM_000152.5(GAA):c.2655_2656del (p.Val886fs)
ENST00000302262.8:c.2655_2656del
ENST00000302262.7:c.2655_2656del
ENST00000390015.7:c.2655_2656del
ENST00000573556.1:n.608_609del
NM_000152.3:c.2655_2656del
NM_001079803.1:c.2655_2656del
NM_001079804.1:c.2655_2656del
NM_000152.4:c.2655_2656del
NM_001079803.2:c.2655_2656del
NM_001079804.2:c.2655_2656del
NM_001079803.3:c.2655_2656del
NM_001079804.3:c.2655_2656del
NC_000017.11:g.80118661_80118662del
CM000679.2:g.80118661_80118662del
NC_000017.10:g.78092460_78092461del
CM000679.1:g.78092460_78092461del
NC_000017.9:g.75707055_75707056del
NG_009822.1:g.22106_22107del

Pathogenic

Met criteria codes 4
PM2_Supporting PVS1 PM3_Supporting PP4_Moderate

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.2655_2656del (p.Val886GlufsTer2) variant in GAA is a frameshift variant predicted to cause a premature stop codon and to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Two siblings with this variant and late-onset Pompe disease have been reported with GAA activity in dried blood spots below the normal range, and both are on enzyme replacement therapy (PMID 31392188, personal communication)(PP4_Moderate). These individuals are compound heterozygous for the variant and a pathogenic variant in GAA, c.-32-13T>G, phase unknown (PM3_Supporting). The variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 597005; 1 star review status) with one submitter classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP (Specifications Version 2.0): PVS1, PP4_Moderate, PM2_Supporting, PM3_Supporting.
Met criteria codes
PM2_Supporting
This variant is absent in gnomAD v2.1.1 (PM2_Supporting).
PVS1
The NM_000152.5:c.2655_2656del (p.Val886GlufsTer2) variant in GAA is a frameshift variant predicted to cause a premature stop codon and to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
PM3_Supporting
Two siblings with late-onset Pompe disease are compound heterozygous for the variant and c.-32-13T>G, a known pathogenic variant in GAA (PMID 31392188). The phase is unknown. Total 0.5 points (PM3_Supporting).
PP4_Moderate
Two siblings with Pompe disease who are compound heterozygous have documented GAA activity in dried blood spot below the normal range, and both are on enzyme replacement therapy (PMID 31392188, personal communication)meeting the ClinGen LSD VCEP's specifications for PP4_Moderate.
Approved on: 2021-09-01
Published on: 2021-09-28
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.